Each MyHep All tablet contains Sofosbuvir 400 mg and Velpatasvir 100 mg.
Description:
MyHep All is a fixed-dose combination tablet containing sofosbuvir and velpatasvir for oral administration. Sofosbuvir is a nucleotide analog HCV NS5B polymerase inhibitor and velpatasvir is an NS5A inhibitor.
Indications:
MyHep All is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) infection.
Dosage:
The recommended dosage of MyHep All is one tablet taken orally once daily with or without food.
